Advertisement
Advertisement
U.S. markets close in 4 hours 18 minutes
Advertisement
Advertisement
Advertisement
Advertisement

electroCore, Inc. (ECOR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.9575+0.0037 (+0.39%)
As of 11:42AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.9538
Open0.9600
Bid0.9450 x 900
Ask0.9463 x 1300
Day's Range0.9400 - 0.9651
52 Week Range0.9050 - 3.6300
Volume252,131
Avg. Volume1,870,503
Market Cap66.599M
Beta (5Y Monthly)1.17
PE Ratio (TTM)N/A
EPS (TTM)-0.4820
Earnings DateNov 10, 2021 - Nov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.55
  • GlobeNewswire

    electroCore to Announce Third Quarter 2021 Financial Results on Thursday, November 4th

    ROCKAWAY, NJ, Oct. 21, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the third quarter ended September 30, 2021 after the close of the market on Thursday, November 4, 2021. Management will host a conference call and webcast at 4:30pm Eastern Time to discuss the financial results and answer questions. Thursday, November 4, 2021, 4:30pm Eastern TimeDomestic: 877-269-7756International

  • GlobeNewswire

    electroCore Announces Publication Reviewing the Prescribing of gammaCore for the Treatment of Cluster Headache in England

    ROCKAWAY, NJ, Oct. 20, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper entitled “Non-invasive vagus nerve stimulation for treatment of cluster headache: a retrospective review of prescribing in England,” in the British Journal of Healthcare Management. The paper reviews the prescribing trends of gammaCore in England from April 2019 through the end of 2020. gammaCore was listed o

  • GlobeNewswire

    electroCore Announces Regulatory Approval in Canada to Treat Adolescent Migraine

    Health Canada expands gammaCore label to include the acute and preventive treatment of migraine in adolescentsROCKAWAY, NJ, Oct. 14, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that the company received an amended Medical Device License from Health Canada to expand the label of gammaCore nVNS to include the acute and preventive treatment of migraine in adolescents between 12 and 17 years of age. gammaCore is now cl

Advertisement
Advertisement